Stammdaten
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Unternehmen & Branche
| Name | Cellectar Biosciences, Inc. |
|---|---|
| Ticker | CLRB |
| CIK | 0001279704 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 8,2 Mio. USD |
| Beta | 0,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -21,791,037 | -8.35 | 14,978,321 | 8,537,164 | |
| 2025-09-30 | 10-Q | -4,443,877 | -1.41 | 14,627,590 | 7,997,306 | |
| 2025-06-30 | 10-Q | -5,447,911 | -3.39 | 13,695,183 | 6,085,012 | |
| 2025-03-31 | 10-Q | -6,604,029 | -0.14 | 16,042,190 | 8,253,389 | |
| 2024-12-31 | 10-K | -44,581,446 | -41.89 | 25,474,047 | 14,294,681 | |
| 2024-09-30 | 10-Q | -14,664,719 | -12.13 | 37,293,266 | 15,164,940 | |
| 2024-06-30 | 10-Q | -919,371 | -5.43 | 29,384,657 | 12,380,973 | |
| 2024-03-31 | 10-Q | -26,641,983 | -0.91 | 42,908,439 | 12,501,095 | |
| 2023-12-31 | 10-K | -42,770,610 | -3.50 | 12,075,580 | -15,158,968 | |
| 2023-09-30 | 10-Q | -17,520,378 | -1.55 | 21,550,765 | -28,000,262 | |
| 2023-06-30 | 10-Q | -10,178,640 | -0.90 | 6,509,165 | -8,387,900 | |
| 2023-03-31 | 10-Q | -7,190,470 | -0.76 | 14,838,456 | 1,370,983 | |
| 2022-12-31 | 10-K | -28,601,254 | -4.05 | 21,589,790 | 8,153,244 | |
| 2022-09-30 | 10-Q | -7,811,322 | -1.28 | 19,319,513 | 12,750,509 | |
| 2022-06-30 | 10-Q | -7,435,043 | -1.22 | 25,892,396 | 20,194,072 | |
| 2022-03-31 | 10-Q | -6,139,797 | -1.00 | 31,990,186 | 27,209,162 | |
| 2021-12-31 | 10-K | -24,122,362 | -4.35 | 37,201,809 | 33,045,154 | |
| 2021-09-30 | 10-Q | -5,819,064 | -0.97 | 41,953,269 | 38,585,404 | |
| 2021-06-30 | 10-Q | -6,028,030 | -1.14 | 47,737,858 | 43,983,307 | |
| 2021-03-31 | 10-Q | -6,357,170 | -0.13 | 55,064,779 | 49,775,847 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.